Delta Sleep-Inducing Peptide Doesn't Meaningfully Improve Sleep in Insomniacs

Delta sleep-inducing peptide (DSIP) administered intravenously at 25 nmol/kg over four nights showed some improvements in sleep metrics in chronic insomniacs — including reduced awakenings, decreased waking time, and increased total sleep time — but these changes were not statistically significant compared to placebo. The only significant increases were in NREM sleep time and stage 2 sleep, but these differences already existed at baseline, undermining the finding. The authors concluded that DSIP's sleep-improving effects are of little clinical significance.

This was a double-blind, placebo-controlled crossover trial in chronic insomnia patients. DSIP (25 nmol/kg) or placebo was administered intravenously over four nights. Sleep was measured using polysomnographic recordings, tracking sleep stages, awakenings, latency, and total sleep time.

DSIP was once considered a promising natural sleep peptide, but this rigorous double-blind, placebo-controlled trial found it doesn't meaningfully improve sleep in chronic insomniacs. This is an important negative result that helps explain why DSIP never became a clinical sleep treatment despite decades of interest. It underscores the gap between a peptide's name and its actual therapeutic utility.

DSIP was discovered in 1977 and generated enormous excitement as a potential natural sleep drug. This 1987 trial was one of several that ultimately showed it doesn't live up to its name in clinical settings. The story of DSIP illustrates a common pattern in peptide research: a molecule discovered through its effects in animal models fails to translate to meaningful therapeutic benefit in humans. Despite this, DSIP remains of interest in nootropic and peptide research communities.

Sample size not specified in abstract but likely small. The short 4-night treatment period may not capture potential longer-term effects. Only one dose was tested. The IV route of administration limits practical applicability. The crossover design, while rigorous, may have been affected by carryover or period effects.